Related Experiment Video

Updated: May 17, 2026

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension
05:57

The Antihypertensive Effects and Mechanisms of Huotan Jiedu Tongluo Decoction in Rats with H-Type Hypertension

Published on: May 17, 2024

Updating the relationship between hyperhomocysteinemia lowering therapy and cardiovascular events

Xiaoshu Cheng1

  • 1Department of Cardiology, Second Affiliated Hospital, Nanchang University, Nanchang, China. xiaoshu.cheng@gmail.com

Cardiovascular Therapeutics
|October 23, 2012
PubMed

Insights

High homocysteine levels are a risk factor for cardiovascular events. This review examines homocysteine metabolism and recent findings on Hhcy-lowering therapy

Area of Science:

  • Cardiovascular Medicine
  • Metabolic Research

Background:

  • Hyperhomocysteinemia (Hhcy) is recognized as an independent risk factor for cardiovascular events.
  • Numerous clinical trials have explored the link between Hhcy-lowering treatments and cardiovascular disease outcomes.
  • Existing research findings on this topic remain controversial and inconclusive.

Purpose of the Study:

  • To provide an overview of homocysteine metabolism.
  • To update and synthesize recent findings on the efficacy of Hhcy-lowering therapy in preventing cardiovascular events.

Main Methods:

  • Systematic review of existing literature.
  • Analysis of recently published clinical trial results.
  • Synthesis of data on homocysteine metabolism pathways.

Main Results:

  • The review consolidates information on the complex metabolism of homocysteine.
  • Recently published studies offer updated insights into the role of Hhcy-lowering interventions.
  • Controversies surrounding the cardiovascular benefits of Hhcy-lowering therapy are highlighted.

Conclusions:

  • Understanding homocysteine metabolism is crucial for cardiovascular risk assessment.
  • Further research is needed to clarify the definitive role of Hhcy-lowering therapy in cardiovascular event prevention.
  • The controversial nature of current evidence underscores the need for more robust clinical trials.

Keywords:
B vitaminCardiovascular diseaseFolic acidHomocysteine

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...